Ventricular septal defect

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ventricular septal defect
Classification and external resources
Vsd simple-lg.jpg
Illustration showing a ventricular septal defect
ICD-10 Q21.0
ICD-9 745.4
DiseasesDB 13808
MedlinePlus 001099
eMedicine med/3517
MeSH C14.240.400.560.540

A ventricular septal defect (VSD) is a defect in the ventricular septum, the wall dividing the left and right ventricles of the heart.

The ventricular septum consists of an inferior muscular and superior membranous portion and is extensively innervated with conducting cardiomyocytes.

The membranous portion, which is close to the atrioventricular node, is most commonly affected in adults and older children in the United States.[1] It is also the type that will most commonly require surgical intervention, comprising over 80% of cases.[2]

Membranous ventricular septal defects are more common than muscular ventricular septal defects, and are the most common congenital cardiac anomaly. [3]

Classification[edit]

Although there are several classifications for VSD, the most accepted and unified classification is that of Congenital Heart Surgery Nomenclature and Database Project.[4] The classification is based on the location of the VSD on the right ventricular surface of the inter ventricular septum and is as follows:

1. Multiple[edit]

2. Type 1 (Subarterial) (Supracristal) (Conal septal defect) (Infundibular)[edit]

  • Found in 5-7% of patients, more in Asians, related to the pulmonary valve

3. Type 2 (Perimembranous) (Paramembranous) (Conoventricular)[edit]

  • Most common variety found in 70%

4. Type 3 (Inlet) (AV canal type)[edit]

5. Type 4 (Muscular)[edit]

  • Located in the muscular septum, found in 20%. Can be sub classified again based on the location into anterior, apical, posterior and mid

6. Type: Gerbode (Left ventricular to right atrial communication)[edit]

  • Due to absence of Atrioventricular septum.

Diagnosis[edit]

Echocardiographic image of a moderate ventricular septal defect in the mid-muscular part of the septum. The trace in the lower left shows the flow during one complete cardiac cycle and the red mark the time in the cardiac cycle that the image was captured. Colours are used to represent the velocity of the blood. Flow is from the left ventricle (right on image) to the right ventricle (left on image). The size and position is typical for a VSD in the newborn period.

A VSD can be detected by cardiac auscultation. Classically, a VSD causes a pathognomonic holo- or pansystolic murmur. Auscultation is generally considered sufficient for detecting a significant VSD. The murmur depends on the abnormal flow of blood from the left ventricle, through the VSD, to the right ventricle. If there is not much difference in pressure between the left and right ventricles, then the flow of blood through the VSD will not be very great and the VSD may be silent. This situation occurs a) in the fetus (when the right and left ventricular pressures are essentially equal), b) for a short time after birth (before the right ventricular pressure has decreased), and c) as a late complication of unrepaired VSD. Confirmation of cardiac auscultation can be obtained by non-invasive cardiac ultrasound (echocardiography). To more accurately measure ventricular pressures, cardiac catheterization, can be performed.

Pathophysiology[edit]

During ventricular contraction, or systole, some of the blood from the left ventricle leaks into the right ventricle, passes through the lungs and reenters the left ventricle via the pulmonary veins and left atrium. This has two net effects. First, the circuitous refluxing of blood causes volume overload on the left ventricle. Second, because the left ventricle normally has a much higher systolic pressure (~120 mmHg) than the right ventricle (~20 mmHg), the leakage of blood into the right ventricle therefore elevates right ventricular pressure and volume, causing pulmonary hypertension with its associated symptoms.

In serious cases, the pulmonary arterial pressure can reach levels that equal the systemic pressure. This reverses the left to right shunt, so that blood then flows from the right ventricle into the left ventricle, resulting in cyanosis, as blood is by-passing the lungs for oxygenation.[5]

This effect is more noticeable in patients with larger defects, who may present with breathlessness, poor feeding and failure to thrive in infancy. Patients with smaller defects may be asymptomatic. Four different septal defects exist, with perimembranous most common, outlet, atrioventricular, and muscular less commonly.[6]

Signs and symptoms[edit]

Ventricular septal defect is usually symptomless at birth. It usually manifests a few weeks after birth.

Symptoms[edit]

VSD is an acyanotic congenital heart defect, aka a Left-to-right shunt, so there are no signs of cyanosis in the early stage. However, uncorrected VSD can increase pulmonary resistance leading to the reversal of the shunt and corresponding cyanosis.

Signs[edit]

  • Pansystolic (Holosystolic) murmur along lower left sternal

border(depending upon the size of the defect) +/- palpable thrill (palpable turbulence of blood flow). Heart sounds are normal. Larger VSDs may cause a parasternal heave, a displaced apex beat (the palpable heartbeat moves laterally over time, as the heart enlarges). An infant with a large VSD will fail to thrive and become sweaty and tachypnoeic (breathe faster) with feeds.[7]

The restrictive VSDs (smaller defects) are associated with a louder murmur and more palpable thrill (grade IV murmur). Larger defects may eventually be associated with pulmonary hypertension due to the increased blood flow. Over time this may lead to an [[Eisenmenger's syndrome|Eisenmenger phenomenon]]: the original VSD operating with a left-to-right shunt, now becomes a right-to-left shunt because of the increased pressures in the pulmonary vascular bed.

CAUSES: The cause of VSD (ventricular septal defect) includes the incomplete looping of the heart during days 24-28 of development. Faults with NKX2.5 gene can cause this.

Treatment[edit]

A nitinol device for closing muscular VSDs, 4 mm diameter in the centre. It is shown mounted on the catheter into which it will be withdrawn during insertion.

Most cases do not need treatment and heal at the first years of life. Treatment is either conservative or surgical. Smaller congenital VSDs often close on their own, as the heart grows, and in such cases may be treated conservatively. Some cases may necessitate surgical intervention, i.e. with the following indications:

1. Failure of congestive cardiac failure to respond to medications

2. VSD with pulmonic stenosis

3. Large VSD with pulmonary hypertension

4. VSD with aortic regurgitation

For the surgical procedure, a heart-lung machine is required and a median sternotomy is performed. Percutaneous endovascular procedures are less invasive and can be done on a beating heart, but are only suitable for certain patients. Repair of most VSDs is complicated by the fact that the conducting system of the heart is in the immediate vicinity.

Ventricular septum defect in infants is initially treated medically with cardiac glycosides (e.g., digoxin 10-20 µg/kg per day), loop diuretics (e.g., furosemide 1–3 mg/kg per day) and ACE inhibitors (e.g., captopril 0.5–2 mg/kg per day).

Amplatzer® Septal Occluder[edit]

Composition of the Device[edit]

The Amplatzer® Septal Occluden is a device originally used to close openings between the left and right atrium of the heart.[8] It is now also used to close ventricular septal defects (VSD) in the heart.[9] It is a self-expandable device made of Nitril wire consisting of 2 flat discs separated by a central connecting waist.[10] The discs contain some Dacron fabric to enhance local thrombosis for proper healing post insertion of the device.[11] The diameter of the discs is 8mm larger than the central connecting waist, which determines the size of the device.[10] It contains a higher waist-to-disc ratio compared to other occluders.[12] The Amplatzer delivery system of includes a delivery cable and a pusher catheter to allow for proper insertion of the device into the septal defect.[10] The device is designed to block the hole in the membranous septum, with the discs lying on both sides of the wall surrounding the hole.[10] Cardiac tissue is naturally developed around the Amplatzer®, becoming part of the membranous septum and sealing the defective hole.[10] Amplatzer is not to be used for patients with infections, extensive cardiac abnormalities, blood clots or patients who are allergic to nickel or cannot use blood-thinners.[8]

The non-surgical procedure[edit]

The Amplatzer® Septal Occluder comes in different sizes and the size is determined by the area of the defect, which is measured at the end of diastole.[9] The non-surgical installation procedure is done with the aid of trans-esophageal echocardiogram (TEE) and fluoroscopic monitoring.[9] There is also an angiogram in the long axial oblique view for viewing of the left ventricle during the procedure.[9] For closure of a VSD, a left and right heart catheter is inserted into the patient through the femoral vein and the VSD is crossed in a retrograde fashion.[9] The catheter is then replaced with a softer wire.[9] This new wire is directed into the pulmonary artery, snared, then exteriorized through the femoral vein.[9] This will form a stable arteriovenous loop.[9] The Amplatzer® Septal Occluder is then pushed to the tip of the delivery cable and the first disc is inserted into the left ventricle.[9] With a slight pull of the device the middle-connecting waist is released and the delivery cable is in the right ventricle of the heart.[9] The right ventricular disc is deployed by yet another pull of the delivery cable.[9] TEE is performed before and after implantation of the device to ensure proper placement.[9]

Advantages and Disadvantages[edit]

The Amplatzer® Septal Occluder was shown to have full closure of the ventricular defect within the 24 hours of placement.[9] It has a low risk of embolism after implantation.[12] Some tricuspid valve regurgitation was shown after the procedure that could possibly be due from the right ventricular disc.[9] There have been some reports that the Amplatzer® Septal Occluder may cause life-threatening erosion of the tissue inside the heart.[13] This occurs in one percent of the patients implanted with the device and requires immediate open-heart surgery.[13] This erosion occurs due to improper sizing of the device resulting with it being too large for the defect, causing rubbing of the septal tissue and erosion.[13]

Surgical technique for Repair of Perimembranous VSD[edit]

a) Surgical closure of a Perimembranous VSD is performed on cardiopulmonary bypass with ischemic arrest. Patients are usually cooled to 28 degrees. Percutaneous Device closure of these defects is rarely performed in the United States because of the reported incidence of both early and late onset complete heart block after device closure, presumably secondary to device trauma to the AV node.

b) Surgical exposure is achieved through the right atrium. The tricuspid valve septal leaflet is retracted or incised to expose the defect margins.

c) Several patch materials are available, including native pericardium, bovine pericardium, PTFE (Gore-Tex or Impra), or Dacron.

d) Suture techniques include horizontal pledgeted mattress sutures, and running polypropylene suture.

e) Critical attention is necessary to avoid injury to the conduction system located on the left ventricular side of the interventricular septum near the papillary muscle of the conus.

f) Care is taken to avoid injury to the aortic valve with sutures.

g) Once the repair is complete, the heart is extensively deaired by venting blood through the aortic cardioplegia site, and by infusing Carbon Dioxide into the operative field to displace air.

h) Intraoperative transesophageal echocardiography is used to confirm secure closure of the VSD, normal function of the aortic and tricuspid valves, good ventricular function, and the elimination of all air from the left side of the heart.

i) The sternum, fascia and skin are closed, with potential placement of a local anesthetic infusion catheter under the fascia, to enhance postoperative pain control.

j) A video of Perimembranous VSD repair, including the operative technique, and the daily postoperative recovery, can be seen here: VSD Repair, Perimembranous Ventricular Septal Defect i

Epidemiology and Etiology[edit]

VSDs are the most common congenital cardiac anomalies. They are found in 30-60% of all newborns with a congenital heart defect, or about 2-6 per 1000 births. During heart formation, when the heart begins life as a hollow tube, it begins to partition, forming septa. If this does not occur properly it can lead to an opening being left within the ventricular septum. It is debatable whether all those defects are true heart defects, or if some of them are normal phenomena, since most of the trabecular VSDs close spontaneously.[14] Prospective studies give a prevalence of 2-5 per 100 births of trabecular VSDs that closes shortly after birth in 80-90% of the cases.[15][16]

Congenital VSDs are frequently associated with other congenital conditions, such as Down syndrome.[17]

A VSD can also form a few days after a myocardial infarction[18] (heart attack) due to mechanical tearing of the septal wall, before scar tissue forms, when macrophages start remodeling the dead heart tissue.

See also[edit]

Additional images[edit]

References[edit]

  1. ^ Taylor, Michael D. "Muscular Ventricular Septal Defect". eMedicine. Medscape. 
  2. ^ Waight, David J.; Bacha, Emile A.; Kahana, Madelyn; Cao, Qi-Ling; Heitschmidt, Mary; Hijazi, Ziyad M. (March 2002). "Catheter therapy of Swiss cheese ventricular septal defects using the Amplatzer muscular VSD occluder". Catheterization and Cardiovascular Interventions 55 (3): 355–361. doi:10.1002/ccd.10124. PMID 11870941. 
  3. ^ Hoffman, JI; Kaplan, S (2002). "The incidence of congenital heart disease". Journal of the American College of Cardiology 39 (12): 1890–900. doi:10.1016/S0735-1097(02)01886-7. PMID 12084585. 
  4. ^ Jacobs, Jeffrey; Mavroudis, Constantine (March 2000). "Congenital Heart Surgery Nomenclature and Database Project: ventricular septal defect". Ann Thorac Surg 69 (3): 25–35. doi:10.1016/S0003-4975(99)01270-9. PMID 10798413. 
  5. ^ Kumar & Clark 2009
  6. ^ Mancini, Mary C. "Ventricular Septal Defect Surgery in the Pediatric Patient". eMedicine. Medscape. 
  7. ^ Cameron P. et al: Textbook of Pediatric Emergency Medicine. p116-117 [Elsevier, 2006]
  8. ^ a b AMPLATZER® Septal Occluder. (2013) U.S. Food and Drug Administration. Retrieved February 26, 2014, from http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm083978.htm
  9. ^ a b c d e f g h i j k l m n Szkutnik et al. (2007) “Use of the Amplatzer muscular ventricular septal defect occluder for closure of perimembranous ventricular septal defects.” Heart. 93:355–358.
  10. ^ a b c d e Carminati, Mano et al. (2005) “Transcatheter Closure of Congenital Ventricular Septal Defect with Amplatzer Septal Occludenr”. The American Journal of Cardiology. 96(12A): 52L-58L.
  11. ^ Holzer, Ralf et al. (2004) “Device Closure of Muscular Ventricular Septal Defects Using the Amplatzer Muscular Ventricular Septal Defect Occluder.” Journal of the American College of Cardiology. 43(7): 1257-1263.
  12. ^ a b Fernando, Rajeev et al. (2013). “Patent ductus arteriosus closure using an Amplatzer™ ventricular septal defect closure device ”. Experimental & Clinical Cardiology, 18(1), e50-e54.
  13. ^ a b c Rare Serious Erosion Events Associated with St. Jude Amplatzer Atrial Septal Occluder (ASO). (2013, October 17). U.S. Food and Drug Administration. Retrieved February 26, 2014, from http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm371145.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery
  14. ^ Meberg, A; Otterstad, JE; Frøland, G; Søarland, S; Nitter-Hauge, S (1994). "Increasing incidence of ventricular septal defects caused by improved detection rate". Acta Pædiatrica 83 (6): 653–657. doi:10.1111/j.1651-2227.1994.tb13102.x. 
  15. ^ Hiraishi, S; Agata, Y; Nowatari, M; Oguchi, K; Misawa, H; Hirota, H; Fujino, N; Horiguchi, Y; Yashiro, K; Nakae, S (March 1992). "Incidence and natural course of trabecular ventricular septal defect: two-dimensional echocardiography and color Doppler flow imaging study.". The Journal of pediatrics 120 (3): 409–15. doi:10.1016/s0022-3476(05)80906-0. PMID 1538287. 
  16. ^ Roguin, Nathan; Du, Zhong-Dong; Barak, Mila; Nasser, Nadim; Hershkowitz, Sylvia; Milgram, Elliot (15 November 1995). "High prevalence of muscular ventricular septal defect in neonates". Journal of the American College of Cardiology 26 (6): 1545–1548. doi:10.1016/0735-1097(95)00358-4. PMID 7594083. 
  17. ^ Wells, GL; Barker, SE; Finley, SC; Colvin, EV; Finley, WH (1994). "Congenital heart disease in infants with Down's syndrome". Southern Medical Journal 87 (7): 724–7. doi:10.1097/00007611-199407000-00010. PMID 8023205. 
  18. ^ Schumacher, Kurt R. "Ventricular septal defect". NIH and US National Library of Medicine. MedlinePlus. 

External links[edit]